Table 2:
Multivariable analysis
| Hazard ratio (95% CI) | p value* | |
|---|---|---|
| Progression-free survival (Phoenix definition) | ||
| Treatment group | ||
| NHT plus WPRT | 1 (ref) | .. |
| NHT plus PORT | 1·21 (1·02–1·43) | 0·027 |
| WPRT plus AHT | 1·21 (1·03–1·43) | 0·025 |
| PORT plus AHT | 0·93 (0·78–1·10) | 0·39 |
| Gleason Score | ||
| 2–6 | 1 (ref) | .. |
| 7–10 | 1·27 (1·11–1·45) | 0·0006 |
| PSA level (ng/mL) | ||
| ≤30 | 1 (ref) | .. |
| >30 | 1·43 (1·26–1·63) | <0·0001 |
| T stage | ||
| T1c or T2a | 1 (ref) | .. |
| T1b or T2b | 0·96 (0·76–1·20) | 0·71 |
| T2c–T4 | 1·05 (0·90–1·21) | 0·54 |
| Phoenix biochemical failure | ||
| Treatment group | ||
| NHT plus WPRT | 1 (ref) | .. |
| NHT plus PORT | 1·38 (1·11–1·72) | 0·0045 |
| WPRT plus AHT | 1·11 (0·89–1·40) | 0·35 |
| PORT plus AHT | 1·00 (0·9–1·27) | 0·97 |
| Gleason Score | ||
| 2–6 | 1 (ref) | .. |
| 7–10 | 1·42 (1·18–1·71) | 0·0002 |
| PSA level, ng/mL | ||
| ≤30 | 1 (ref) | .. |
| >30 | 1·59 (1·33–1·89) | <0·0001 |
| T stage | ||
| T1c or T2a | 1 (ref) | .. |
| T1b or T2b | 1·23 (0·92–1·64) | 0·15 |
| T2c–T4 | 1·22 (0·998–1·49) | 0·052 |
NHT=neoadjuvant hormonal therapy. WPRT=whole pelvic radiotherapy. PORT=prostate only radiotherapy. AHT=adjuvant hormonal therapy. PSA=prostate-specific antigen.
*
χ2 using the Cox proportional hazards model for progression-free survival and from the Fine-Gray regression model for Phoenix biochemical failure.